Journal article
Selection and management of older patients with acute myeloid leukemia treated with glasdegib plus low-dose cytarabine: expert panel review
Abstract
Glasdegib, in combination with low-dose cytarabine (LDAC), is the first smoothened inhibitor approved for treatment of acute myeloid leukemia. Glasdegib plus LDAC is indicated for patients in whom therapy options are limited, e.g. older patients and those ineligible for intensive chemotherapy due to preexisting comorbidities. This review summarizes the recommendations of a panel of hemato-oncologists regarding the selection of patients best …
Authors
Cortes JE; Candoni A; Clark RE; Leber B; Montesinos P; Vyas P; Zeidan AM; Heuser M
Journal
Leukemia & Lymphoma, Vol. 61, No. 14, pp. 3287–3305
Publisher
Taylor & Francis
Publication Date
December 5, 2020
DOI
10.1080/10428194.2020.1817445
ISSN
1042-8194